{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:42:46Z","timestamp":1787020966502,"version":"build-2736575974"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"crossref","award":["668353"],"award-info":[{"award-number":["668353"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hum Genomics"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Myelodysplastic syndromes (MDS) consist of a group of hematological malignancies characterized by ineffective hematopoiesis, cytogenetic abnormalities, and often a high risk of transformation to acute myeloid leukemia (AML). So far, there have been only a very limited number of studies assessing the epigenetics component contributing to the pathophysiology of these disorders, but not a single study assessing this at a genome-wide level. Here, we implemented a generic high throughput epigenomics approach, using methylated DNA sequencing (MeD-seq) of LpnPI digested fragments to identify potential epigenomic targets associated with MDS subtypes. Our results highlighted that\n                    <jats:italic>PCDHG<\/jats:italic>\n                    and\n                    <jats:italic>ZNF<\/jats:italic>\n                    gene families harbor potential epigenomic targets, which have been shown to be differentially methylated in a variety of comparisons between different MDS subtypes. Specifically, CpG islands, transcription start sites and post-transcriptional start sites within\n                    <jats:italic>ZNF124<\/jats:italic>\n                    ,\n                    <jats:italic>ZNF497<\/jats:italic>\n                    and\n                    <jats:italic>PCDHG<\/jats:italic>\n                    family are differentially methylated with fold change above 3,5. Overall, these findings highlight important aspects of the epigenomic component of MDS syndromes pathogenesis and the pharmacoepigenomic basis to the hypomethylating agents drug treatment response, while this generic high throughput whole epigenome sequencing approach could be readily implemented to other genetic diseases with a strong epigenetic component.\n                  <\/jats:p>","DOI":"10.1186\/s40246-023-00483-7","type":"journal-article","created":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T04:02:32Z","timestamp":1682395352000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Genome-wide analysis toward the epigenetic aetiology of myelodysplastic syndrome disease progression and pharmacoepigenomic basis of hypomethylating agents drug treatment response"],"prefix":"10.1186","volume":"17","author":[{"given":"Stavroula","family":"Siamoglou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Boers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Koromina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Boers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Tsironi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodora","family":"Chatzilygeroudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasileios","family":"Lazaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgenia","family":"Verigou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Kourakli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfred F. J.","family":"van IJcken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost","family":"Gribnau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Argiris","family":"Symeonidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George P.","family":"Patrinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,25]]},"reference":[{"key":"483_CR1","doi-asserted-by":"crossref","unstructured":"Malcovati L, Hellstr\u00f6m E, Hellstr\u00f6m-Lindberg H, Bowen D, Ad\u00e8s L, Ad\u00e8s A, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. 2013","DOI":"10.1182\/blood-2013-03-492884"},{"key":"483_CR2","doi-asserted-by":"crossref","unstructured":"Chung SS, Park CY. Aging, hematopoiesis, and the myelodysplastic syndromes. Blood Adv. Am. Soc. Hematol. 2017. p. 2572\u20138.","DOI":"10.1182\/bloodadvances.2017009852"},{"key":"483_CR3","doi-asserted-by":"crossref","unstructured":"Sallman DA, Padron E. Myelodysplasia in younger adults: Outlier or unique molecular entity? Haematologica. 2017. p. 967\u20138.","DOI":"10.3324\/haematol.2017.165993"},{"key":"483_CR4","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1016\/j.leukres.2011.06.001","volume":"35","author":"J Neukirchen","year":"2011","unstructured":"Neukirchen J, Schoonen WM, Strupp C, Gattermann N, Aul C, Haas R, et al. Incidence and prevalence of myelodysplastic syndromes: Data from the D\u00fcsseldorf MDS-registry. Leuk Res. 2011;35:1591\u20136.","journal-title":"Leuk Res"},{"key":"483_CR5","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1002\/cncr.22570","volume":"109","author":"X Ma","year":"2007","unstructured":"Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007;109:1536\u201342.","journal-title":"Cancer"},{"key":"483_CR6","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00277-013-1712-6","volume":"92","author":"C Avgerinou","year":"2013","unstructured":"Avgerinou C, Alamanos Y, Zikos P, Lampropoulou P, Melachrinou M, Labropoulou V, et al. The incidence of myelodysplastic syndromes in Western Greece is increasing. Ann Hematol. 2013;92:877\u201387.","journal-title":"Ann Hematol"},{"key":"483_CR7","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","volume":"122","author":"E Papaemmanuil","year":"2013","unstructured":"Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122:3616\u201327.","journal-title":"Blood"},{"key":"483_CR8","doi-asserted-by":"crossref","unstructured":"Symeonidis A, Kouraklis-Symeonidis A. Immune dysregulation in myelodysplastic syndromes: pathogenetic-pathophysiologic aspects and clinical consequences. Myelodysplastic Syndr. IntechOpen; 2016","DOI":"10.5772\/64618"},{"key":"483_CR9","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0065-2601(08)60016-7","volume":"29","author":"J Greenberg","year":"1997","unstructured":"Greenberg J, Solomon S, Pyszczynski T. Terror management theory of self-esteem and cultural worldviews: empirical assessments and conceptual refinements. Adv Exp Soc Psychol. 1997;29:61\u2013139.","journal-title":"Adv Exp Soc Psychol"},{"key":"483_CR10","first-page":"2454","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sol\u00e9 F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood Am Soc Hematol. 2012;120:2454\u201365.","journal-title":"Blood Am Soc Hematol"},{"key":"483_CR11","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1038\/s41375-021-01218-0","volume":"35","author":"J Stomper","year":"2021","unstructured":"Stomper J, Rotondo JC, Greve G, L\u00fcbbert M. Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies. Leuk. 2021;35:1873\u201389.","journal-title":"Leuk"},{"key":"483_CR12","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","volume":"31","author":"M Leukemia","year":"2013","unstructured":"Leukemia M, Itzykson R, Kosmider O, Renneville A, Gelsi-Boyer V, Meggendorfer M, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol. 2013;31:2428\u201336.","journal-title":"J Clin Oncol"},{"key":"483_CR13","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1038\/leu.2011.170","volume":"25","author":"MT Voso","year":"2011","unstructured":"Voso MT, Fabiani E, Piciocchi A, Matteucci C, Brandimarte L, Finelli C, et al. Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-Azacytidine. Leuk. 2011;25:1910\u20133.","journal-title":"Leuk"},{"key":"483_CR14","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s12308-008-0019-3","volume":"2","author":"D Ye","year":"2009","unstructured":"Ye D, Garcia-Manero G, Kantarjian HM, Xiao L, Vadhan-Raj S, Fernandez MH, et al. Analysis of Aurora kinase A expression in CD34+ blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia. J Hematop. 2009;2:2\u20138.","journal-title":"J Hematop"},{"key":"483_CR15","first-page":"491","volume":"54","author":"G Zhao","year":"2019","unstructured":"Zhao G, Li N, Li S, Wu W, Wang X, Gu J. High methylation of the 4-aminobutyrate aminotransferase gene predicts a poor prognosis in patients with myelodysplastic syndrome. Int J Oncol. 2019;54:491\u2013504.","journal-title":"Int J Oncol"},{"key":"483_CR16","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1182\/blood-2012-05-429175","volume":"120","author":"P Yan","year":"2012","unstructured":"Yan P, Frankhouser D, Murphy M, Tam HH, Rodriguez B, Curfman J, et al. Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia. Blood. 2012;120:2466\u201374.","journal-title":"Blood"},{"key":"483_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-020-03213-2","volume":"11","author":"J Zhou","year":"2020","unstructured":"Zhou J, Zhang T, Xu Z, Deng Z, Gu Y, Ma J, et al. Genome-wide methylation sequencing identifies progression-related epigenetic drivers in myelodysplastic syndromes. Cell Death Dis. 2020;11:1\u201315.","journal-title":"Cell Death Dis"},{"key":"483_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.omtn.2019.01.015","volume":"16","author":"C Gu","year":"2019","unstructured":"Gu C, Liu Y, Yin Z, Yang J, Huang G, Zhu X, et al. Discovery of the Oncogenic Parp1, a target of bcr-abl and a potential therapeutic, in mir-181a\/PPFIA1 signaling pathway. Mol Ther Nucleic Acids. 2019;16:1\u201314.","journal-title":"Mol Ther Nucleic Acids"},{"key":"483_CR19","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1631\/jzus.B1000052","volume":"11","author":"L Wang","year":"2010","unstructured":"Wang L, Xu WL, Meng HT, Qian WB, Mai WY, Tong HY, et al. FLT3 and NPM1 mutations in Chinese patients with acute myeloid leukemia and normal cytogenetics. J Zhejiang Univ Sci B. 2010;11:762\u201370.","journal-title":"J Zhejiang Univ Sci B"},{"key":"483_CR20","first-page":"7287","volume":"16","author":"W-J Ding","year":"2018","unstructured":"Ding W-J, Yang Y, Chen Z-X, Wang Y-Y, Dong W-L, Cen J-N, et al. Methylation level of Rap1GAP and the clinical significance in MDS. Oncol Lett. 2018;16:7287\u201394.","journal-title":"Oncol Lett"},{"key":"483_CR21","first-page":"773","volume":"24","author":"YY Zhang","year":"2016","unstructured":"Zhang YY, Xu L, Li DQ, Shao JH, Chen P, Zhao HY, et al. IL-32 mRNA expression of bone marrow stromal cells and its correlation with cell apoptosis in patients with myelodysplastic syndrome. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016;24:773\u20138.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"483_CR22","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1101\/gr.222885.117","volume":"28","author":"R Boers","year":"2018","unstructured":"Boers R, Boers J, de Hoon B, Kockx C, Ozgur Z, Molijn A, et al. Genome-wide DNA methylation profiling using the methylation-dependent restriction enzyme LpnPI. Genome Res. 2018;28:88\u201399.","journal-title":"Genome Res"},{"key":"483_CR23","doi-asserted-by":"crossref","unstructured":"Slot E, Boers R, Boers J, van IJcken WFJ, Tibboel D, Gribnau J, et al. Genome wide DNA methylation analysis of alveolar capillary dysplasia lung tissue reveals aberrant methylation of genes involved in development including the FOXF1 locus. Clin Epigenetics. 2021;13","DOI":"10.1186\/s13148-021-01134-1"},{"key":"483_CR24","doi-asserted-by":"crossref","unstructured":"Timbergen MJM, Boers R, Vriends ALM, Boers J, van IJcken WFJ, Lavrijsen M, et al. Differentially Methylated Regions in Desmoid-Type Fibromatosis: A Comparison Between CTNNB1 S45F and T41A Tumors. Front Oncol. 2020;10.","DOI":"10.3389\/fonc.2020.565031"},{"key":"483_CR25","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.semcdb.2017.07.007","volume":"69","author":"N El Hajj","year":"2017","unstructured":"El Hajj N, Dittrich M, Haaf T. Epigenetic dysregulation of protocadherins in human disease. Semin Cell Dev Biol. 2017;69:172\u201382.","journal-title":"Semin Cell Dev Biol"},{"key":"483_CR26","doi-asserted-by":"publisher","first-page":"5673","DOI":"10.1210\/jc.2018-01471","volume":"104","author":"C Bernardo-Casti\u00f1eira","year":"2019","unstructured":"Bernardo-Casti\u00f1eira C, Vald\u00e9s N, Celada L, Martinez ASJ, S\u00e1enz-De-Santa-Mar\u00eda I, Bay\u00f3n GF, et al. Epigenetic deregulation of protocadherin PCDHGC3 in pheochromocytomas\/paragangliomas associated With SDHB mutations. J Clin Endocrinol Metab. 2019;104:5673\u201392.","journal-title":"J Clin Endocrinol Metab"},{"key":"483_CR27","doi-asserted-by":"publisher","first-page":"4409","DOI":"10.1038\/onc.2011.609","volume":"31","author":"AR Dallosso","year":"2012","unstructured":"Dallosso AR, \u00d8ster B, Greenhough A, Thorsen K, Curry TJ, Owen C, et al. Long-range epigenetic silencing of chromosome 5q31 protocadherins is involved in early and late stages of colorectal tumorigenesis through modulation of oncogenic pathways. Oncogene. 2012;31:4409\u201319.","journal-title":"Oncogene"},{"key":"483_CR28","doi-asserted-by":"crossref","unstructured":"Yu J, Cheng YY, Tao Q, Cheung KF, Lam CNY, Geng H, et al. Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer. Gastroenterology. 2009;136.","DOI":"10.1053\/j.gastro.2008.10.050"},{"key":"483_CR29","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/sj.onc.1209154","volume":"25","author":"J Ying","year":"2006","unstructured":"Ying J, Li H, Seng TJ, Langford C, Srivastava G, Tsao SW, et al. Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation. Oncogene. 2006;25:1070\u201380.","journal-title":"Oncogene"},{"key":"483_CR30","doi-asserted-by":"crossref","unstructured":"Xu ZJ, Ma JC, Zhou JD, Wen XM, Yao DM, Zhang W, et al. Reduced protocadherin17 expression in leukemia stem cells: the clinical and biological effect in acute myeloid leukemia. J Transl Med. 2019;17.","DOI":"10.1186\/s12967-019-1851-1"},{"key":"483_CR31","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/path.4093","volume":"229","author":"X Hu","year":"2013","unstructured":"Hu X, Sui X, Li L, Huang X, Rong R, Su X, et al. Protocadherin 17 acts as a tumour suppressor inducing tumour cell apoptosis and autophagy, and is frequently methylated in gastric and colorectal cancers. J Pathol. 2013;229:62\u201373.","journal-title":"J Pathol"},{"key":"483_CR32","doi-asserted-by":"publisher","first-page":"832","DOI":"10.3892\/mmr.2014.2285","volume":"10","author":"Z Li","year":"2014","unstructured":"Li Z, Yang Z, Peng X, Li Y, Liu Q, Chen J. Nuclear factor-\u03baB is involved in the protocadherin-10-mediated pro-apoptotic effect in multiple myeloma. Mol Med Rep. 2014;10:832\u20138.","journal-title":"Mol Med Rep"},{"key":"483_CR33","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1002\/jcb.25135","volume":"116","author":"T Chen","year":"2015","unstructured":"Chen T, Long B, Ren G, Xiang T, Li L, Wang Z, et al. Protocadherin20 acts as a tumor suppressor gene: epigenetic inactivation in nasopharyngeal carcinoma. J Cell Biochem. 2015;116:1766\u201375.","journal-title":"J Cell Biochem"},{"key":"483_CR34","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/jvh.12265","volume":"22","author":"J Lv","year":"2015","unstructured":"Lv J, Zhu P, Yang Z, Li M, Zhang X, Cheng J, et al. PCDH20 functions as a tumour-suppressor gene through antagonizing the Wnt\/\u03b2-catenin signalling pathway in hepatocellular carcinoma. J Viral Hepat. 2015;22:199\u2013209.","journal-title":"J Viral Hepat"},{"key":"483_CR35","doi-asserted-by":"publisher","first-page":"747","DOI":"10.3892\/or.2015.4056","volume":"34","author":"Y Xu","year":"2015","unstructured":"Xu Y, Yang Z, Yuan H, Li Z, Li Y, Liu Q, et al. PCDH10 inhibits cell proliferation of multiple myeloma via the negative regulation of the Wnt\/\u03b2-catenin\/BCL-9 signaling pathway. Oncol Rep. 2015;34:747\u201354.","journal-title":"Oncol Rep"},{"key":"483_CR36","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.yexmp.2016.03.002","volume":"100","author":"Y Yang","year":"2016","unstructured":"Yang Y, Jiang Y, Jiang M, Zhang J, Yang B, She Y, et al. Protocadherin 10 inhibits cell proliferation and induces apoptosis via regulation of DEP domain containing 1 in endometrial endometrioid carcinoma. Exp Mol Pathol. 2016;100:344\u201352.","journal-title":"Exp Mol Pathol"},{"key":"483_CR37","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.3892\/or.2017.5630","volume":"37","author":"M Ye","year":"2017","unstructured":"Ye M, Li J, Gong J. PCDH10 gene inhibits cell proliferation and induces cell apoptosis by inhibiting the PI3K\/Akt signaling pathway in hepatocellular carcinoma cells. Oncol Rep. 2017;37:3167\u201374.","journal-title":"Oncol Rep"},{"key":"483_CR38","doi-asserted-by":"publisher","first-page":"3357","DOI":"10.3892\/ol.2017.6629","volume":"14","author":"Z Zong","year":"2017","unstructured":"Zong Z, Pang H, Yu R, Jiao Y. PCDH8 inhibits glioma cell proliferation by negatively regulating the AKT\/GSK3\u03b2\/\u03b2-catenin signaling pathway. Oncol Lett. 2017;14:3357\u201362.","journal-title":"Oncol Lett"},{"key":"483_CR39","first-page":"2959","volume":"129","author":"A Stoddart","year":"2017","unstructured":"Stoddart A, Wang J, Hu C, Fernald AA, Davis EM, Cheng JX, et al. Inhibition of WNT signaling in the bone marrow niche prevents the development of MDS in the Apcdel\/+ MDS mouse model. Blood Am Soc Hematol. 2017;129:2959\u201370.","journal-title":"Blood Am Soc Hematol"},{"key":"483_CR40","first-page":"509","volume":"42","author":"Y Chen","year":"2019","unstructured":"Chen Y, Zhao G, Li N, Luo Z, Wang X, Gu J. Role of 4-aminobutyrate aminotransferase (ABAT) and the lncRNA co-expression network in the development of myelodysplastic syndrome. Oncol Rep. 2019;42:509\u201320.","journal-title":"Oncol Rep"},{"key":"483_CR41","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s12308-020-00412-w","volume":"13","author":"S Oka","year":"2020","unstructured":"Oka S, Ono K, Nohgawa M. Relationship between p53 expression and prognosis of myelodysplastic syndrome treated with azacitidine. J Hematopathol. 2020;13:213\u20139. https:\/\/doi.org\/10.1007\/s12308-020-00412-w.","journal-title":"J Hematopathol"},{"key":"483_CR42","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1096\/fj.201600846RR","volume":"31","author":"E Dr\u00e1berov\u00e1","year":"2017","unstructured":"Dr\u00e1berov\u00e1 E, Sulimenko V, Vinopal S, Sulimenko T, Sl\u00e1dkov\u00e1 V, D\u2019Agostino L, et al. Differential expression of human \u03b3-tubulin isotypes during neuronal development and oxidative stress points to a \u03b3-tubulin-2 prosurvival function. FASEB J. 2017;31:1828\u201346.","journal-title":"FASEB J"},{"key":"483_CR43","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/ncb1864","volume":"11","author":"C Tian","year":"2009","unstructured":"Tian C, Xing G, Xie P, Lu K, Nie J, Wang J, et al. KRAB-type zinc-finger protein Apak specifically regulates p53-dependent apoptosis. Nat Cell Biol. 2009;11:580\u201391.","journal-title":"Nat Cell Biol"},{"key":"483_CR44","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1038\/sj.emboj.7600791","volume":"24","author":"C Wang","year":"2005","unstructured":"Wang C, Ivanov A, Chen L, Fredericks WJ, Seto E, Rauscher FJ, et al. MDM2 interaction with nuclear corepressor KAP1 contributes to p53 inactivation. EMBO J. 2005;24:3279\u201390.","journal-title":"EMBO J"},{"key":"483_CR45","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S1097-2765(00)00075-7","volume":"6","author":"L Zheng","year":"2000","unstructured":"Zheng L, Pan H, Li S, Flesken-Nikitin A, Chen PL, Boyer TG, et al. Sequence-specific transcriptional corepressor function for BRCA1 through a novel zinc finger protein, ZBRK1. Mol Cell. 2000;6:757\u201368.","journal-title":"Mol Cell"},{"key":"483_CR46","doi-asserted-by":"crossref","unstructured":"Ungerstedt JS. Epigenetic Modifiers in Myeloid Malignancies: The Role of Histone Deacetylase Inhibitors. Int J Mol Sci. 2018;19.","DOI":"10.3390\/ijms19103091"},{"key":"483_CR47","doi-asserted-by":"publisher","first-page":"28812","DOI":"10.18632\/oncotarget.15807","volume":"8","author":"M Tobiasson","year":"2017","unstructured":"Tobiasson M, Abdulkadir H, Lennartsson A, Katayama S, Marabita F, De Paepe A, et al. Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive\/permissive histone marks and gene expression in primary cells from patients with MDS and MDSrelated disease. Oncotarget. 2017;8:28812\u201325.","journal-title":"Oncotarget"}],"container-title":["Human Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40246-023-00483-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40246-023-00483-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40246-023-00483-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T04:09:22Z","timestamp":1682395762000},"score":1,"resource":{"primary":{"URL":"https:\/\/humgenomics.biomedcentral.com\/articles\/10.1186\/s40246-023-00483-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,25]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["483"],"URL":"https:\/\/doi.org\/10.1186\/s40246-023-00483-7","relation":{},"ISSN":["1479-7364"],"issn-type":[{"value":"1479-7364","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,25]]},"assertion":[{"value":"9 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Informed consent was obtained from all subjects involved in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"37"}}